Cara Therapeutics, Inc. (NASDAQ: CARA) shares jumped Wednesday after the company disclosed that its Phase 2/3 trial of I.V. CR845 met primary and secondary endpoints.
A news release issued Wednesday by the Stamford, Conn.-based Cara reported that at the 1.0 mcg/kg dose, I.V. CR845 demonstrated statistically significant reductions in pain intensity compared to placebo at all pre-specified post-operative periods of 0-6 hours (p=0.001); 0-12 hours (p=0.004); 0-18 hours (p=0.013); and 0-24 hours (p=0.032).
Additionally, I.V. CR845 treatment resulted in statistically significant reductions in the incidence of post-operative nausea and vomiting over the 24-hour period post-surgery for both 0.5 and 1.0 mcg/kg doses (p=0.006; p<0.0001, respectively).
Said CEO Derek Chalmers, "We are very pleased that these data demonstrate the overall benefit of I.V. CR845 in both providing pain relief across surgery types up to 24 hours post-surgery and reducing post-operative nausea and vomiting, a significant medical need in the post-operative setting.
"As there continues to be a critical need for new post-surgical analgesics like I.V. CR845 that lack abuse potential and traditional opioid side effects, we will be assessing all options, including discussions with regulators, as to how to best move this program forward."
Cara is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors (KORs). Cara is developing a novel and proprietary class of product candidates, led by KORSUVA™ (CR845/difelikefalin), a first-in-class KOR agonist that targets the body's peripheral nervous system, as well as certain immune cells
Shares in the drug maker galloped $4.16, or 25.3%, to $20.60
Related Stories
